Platelets are the principal cells in thrombosis and haemostasis. Platelets are, however, versatile cells that play important roles in many other physiological and pathophysiological processes, such as inflammation, immunity, angiogenesis, wound healing, and cancer progression ([@bib8]; [@bib17]). It has been well recognised that platelet dysfunction and thrombotic disorders are important manifestations of cancer progression ([@bib8]; [@bib16]; [@bib17]). Thus, cancer patients have a higher risk of platelet hyperactivities ([@bib2]) and thrombotic events ([@bib26]; [@bib24]). Cancer patients diagnosed together with a thrombotic event or thrombocytosis have a poor prognosis of survival ([@bib25]; [@bib6]; [@bib3]).

There are complex cross-talks between platelets and cancer cells ([@bib8]; [@bib17]). Cancer cells can induce platelet activation by releasing various platelet-activating mediators, such as adenosine diphosphate (ADP) ([@bib7]) and thromboxane A~2~ ([@bib27]), and/or by direct cell-to-cell contact ([@bib18]). Hence, different cancer cells may activate platelets via different mechanisms ([@bib8]; [@bib16]; [@bib17]). Moreover, cancer cells may secrete cytokines, including angiogenic regulators, that can be uptaken by platelets ([@bib13]; [@bib14]). By doing so, cancer cells create a tumour-supportive microenvironment, and cancer-'educated' platelets can then promote cancer growth and metastasis ([@bib14]). Indeed, platelets regulate diverse aspects of cancer progression and/or cancer cell activities. Platelets release a number of growth factors that promote cancer cell proliferation (e.g., by platelet-derived growth factor (PDGF)) ([@bib23]) and epithelial--mesenchymal transition (EMT) (by transforming growth factor-1*β* (TGF-1*β*)) ([@bib15]). Platelet adhesion/conjugation on cancer cells can also serve the latter as an immune surveillance-protective 'cloak' ([@bib21]) and facilitates cancer cell arrest at the distal vasculature ([@bib8]; [@bib17]). Moreover, platelets have a rich storage of angiogenic regulators that can not only promote angiogenesis but also prevent haemorrhage in the tumour ([@bib9]). Others and we have recently shown that different stimuli induced selective release of pro-angiogenic or anti-angiogenic regulators from platelet *α*-granules ([@bib19]; [@bib11]; [@bib4]), and that selective platelet release of pro-angiogenic regulators promoted angiogenesis more markedly ([@bib1]; [@bib10]). All these platelet--cancer cell interactions may work in concert to promote cancer growth and metastasis.

Human platelets express protease activated receptor-1 (PAR1) and PAR4 that are best known as thrombin receptors. Interestingly, platelet PAR1 and PAR4 stimulation evoke selective releases of pro-angiogeneic and anti-angiogenic regulators ([@bib19]; [@bib11]; [@bib4]), respectively. Hence, there is a need to investigate how selective releases of platelet angiogenic regulators influence cancer-related angiogenesis and tumour growth. In the present work, we found that PAR1-stimulated platelet releasates (PAR1-PR) and PAR4-stimulated platelet releasates (PAR4-PR) promoted the proliferation of both MCF-7 and MDA-MB-231 breast cancer cells. We also showed that platelet releasates and breast cancer cells collaborated in promoting capillary-like tube formation of endothelial cells. Importantly, we found that PAR1-PR enhanced tumour growth of implanted MDA-MB-231 cells more markedly than PAR4-PR via promoting more intense angiogenesis in the tumour.

Materials and methods
=====================

Study subjects and ethical considerations
-----------------------------------------

Sixteen healthy subjects (9 males and 7 females, aged 28--59 years) gave informed consent to participate in the study. The study was approved by the ethics committee of the Karolinska Institutet in accordance with the guidelines of the Declaration of Helsinki.

Reagents
--------

Thrombin receptor PAR1-activating peptide (PAR1-AP; H-Ser-Phe-Leu-Leu-Arg-Asn-Pro-Asn-Asp-Lys-Tyr-Glu-Pro-Phe-OH), the mitogen-activated protein kinase (MAPK) inhibitor U0126, and the p38-MAPK inhibitor SB203580 were from Calbiochem (Darmstadt, Germany). PAR4-AP (Ala-Tyr-Pro-Gly-Lys-Phe-NH2), prostaglandin (PG) E~1~, aspirin, apyrase grade VII, and cell detach solution (0.01% trypsin/5 mM EDTA) were all purchased from Sigma (St Louis, MO, USA). Recombinant hirudin was from Ciba Geigy (Base, Switzerland). Endothelial culture media (EGM-2 basic medium and the SingleQuots kit) and fetal bovine serum (FBS) were purchased from Lonza (Basel, Switzerland). The VEGFR2 inhibitor Ki8751, the stromal cell-derived factor (SDF)-1*α* receptor CXCR4 inhibitor AMD3100, and RGDS peptide were all from Tocris Bioscience (Bristol, UK). The cell counting kit-8 was from Dojindo (Munich, Germany). The Src kinase inhibitor PP2 and the PI3K inhibitor LY294002 were purchased from Merck Millipore (Darmstadt, Germany). The pan PKC inhibitor Ro 318220 was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).

Culture of HUVECs and cancer cells
----------------------------------

Human umbilical vein endothelial cells (HUVECs) were from Lonza. The HUVECs were cultured using the EGM-2 SingleQuots complete medium containing 10% FBS and the SingleQuots Kit. The HUVECs were cultured with fibronectin-coated 24-well culture plates in an incubator at 37 °C with 5% CO~2~. Human breast cancer cell lines MDA-MB-231 and MCF-7 were from ATCC (Wesel, Germany), and were cultured with RPMI-1640 containing 10% FBS and 1% penicillin--streptomycin at 37 °C with 5% CO~2~. Both cell lines were authenticated through polymorphic short tandem repeat testing within the past 2 years at Uppsala Genome Center (Uppsala, Sweden), and the cells between passages 3 and 10 were used in the present study.

Cell proliferation assay
------------------------

The MCF-7 and MDA-MB-231 cells (1.5 × 10^3^ cells in 100 *μ*l per well) were cultured in a 96-well plate in triplicate with complete medium (RPMI-1640 containing 10% FBS). After 24 h of culture, the medium was replaced by serum-free basic medium without or with platelet releasates. Cell proliferation was determined using a cell counting kit (CCK)-8 assay after 0, 24, 48, 72, and 96 h of incubation, and the absorbance was measured at 450 nm using a microplate reader.

Flow cytometric analysis
------------------------

Cell proliferation was analysed by labelling cells with carboxyfluorescein diacetate succinimidyl ester (CFSE) (Invitrogen, Carlsbad, CA, USA) as described previously ([@bib30]). Briefly, cells were incubated with 1 *μ*M CFSE for 10 min at 37 °C in the dark, washed, and then cultured for 96 h. Cell proliferation was examined at 96 h. For cell apoptosis analyses, the cells were washed with PBS, and stained with Annexin V and propidium iodide (PI) using a commercial kit (V13241; Invitrogen). Flow cytometric analyses were performed using an FC500 flow cytometer (Beckman Coulter, Hialeah, FL, USA).

Preparation of platelet releasates
----------------------------------

Venous blood was collected using 9 ml vacutainers containing 1 : 10 volume of 3.8% sodium citrate and 100 *μ*[M]{.smallcaps} aspirin. Within 3 min of blood collection, blood samples were spun at 190 g for 20 min at room temperature. Upper two-thirds of platelet-rich plasma (PRP) were collected and further centrifuged at 900 g for 10 min in the presence of PGE~1~ (1 *μ*[M]{.smallcaps}). The pellet was resuspended in Tyrode's Hepes buffer containing 1 *μ*[M]{.smallcaps} PGE~1~, centrifuged again, and then resuspended in Tyrode's Hepes buffer containing 20 *μ*g ml^−1^ hirudin and 2 U ml^−1^ apyrase at the concentration of 2 × 10^9^ platelets per ml. The use of aspirin, hirudin, and apyrase was to block the positive feedback of platelet activation upon PAR1 or PAR4 receptor stimulation.

After the recovery of cell reactivity (30 min, 22 °C), platelets were stimulated with PAR1-AP (10 *μ*[M]{.smallcaps}) or PAR4-AP (100 *μ*[M]{.smallcaps}) for 10 min at 37 °C. Afterwards, the samples were centrifuged at 15 000 g for 10 min at 4 °C, and the supernatant was aliquoted and stored at −80 °C. The platelet releasates prepared with the present conditions have been documented by us previously for a selective pro-angiogenic regulator release by PAR1-AP stimulation (e.g., VEGF 50.2±0.9 11.6±1.3 pg ml^−1^ with PAR4-AP) and a selective anti-angiogenic regulator release by PAR4-AP stimulation (PF4 10.5±2.6 *vs* 5.6±0.9 *μ*g ml^−1^ by PAR1-AP) ([@bib4]).

*In vitro* tube formation on Matrigel-coated plates
---------------------------------------------------

Tube formation assay was performed using 96-well plates coated with Matrigel (Corning Inc., Tewksbury, MA, USA). Matrigel was thawed at 4 °C overnight. The solution was added into the wells of a 96-well plate (50 *μ*l per well), and incubated at 37 °C for 1 h to allow matrix gel solidification.

The HUVECs were resuspended in EBM-2 basic medium at 10^5^ per ml. Cell suspensions of MDA-MB-231 and MCF-7 cancer cells (10^6^ per ml for both) were also prepared using EBM-2 basic medium. Afterwards, 10^4^ HUVECs (100 *μ*l cell suspension), 10^4^ cancer cells (10 *μ*l MDA-MB-231 or MCF-7 cell suspension), or/and 10% platelet releasates were added into each matrix gel-coated well and incubated at 37 °C for 6 h. Capillary-like tubular structures were observed using an Olympus CKX41 inverted light microscope (Olympus Life Science, Tokyo, Japan) equipped with a Nikon D5100 camera (Tokyo, Japan). The branch points of capillary-like structure were assessed using the Wimasis software (Munich, Germany).

*In vivo* experiments of tumour growth
--------------------------------------

The protocol of *in vivo* tumour growth using a murine model of Matrigel implantation was approved by the institutional animal care and use committee of the Second Hospital of Shandong University. The study was performed in accordance to the national guidelines of China on 'Laboratory animals-requirements of environment and housing facilities' (GB 14925-2001) and to the European Directive 2010/63/EU on the protection of animals used for scientific purposes. Twenty-five female nude mice (8--12 weeks) were obtained from the Model Animal Research Center of Nanjing University (Nanjing, China).

Matrigel implantation cocktails (final volume at 250 *μ*l per implant site) were composed immediately before use. The cocktails contained no cells or 10^6^ MDA-MB-231 breast cancer cells. The cocktails were also supplemented with 10% (final concentration) of either vehicle (Tyrode's Hepes buffer containing 20 *μ*g ml^−1^ hirudin and 2 U ml^−1^ apyrase without or with 1 *μ*[M]{.smallcaps} PAR1-AP or 10 *μ*[M]{.smallcaps} PAR4-AP), PAR1-PR, or PAR4-PR. Two pairs of Matrigel implantations were made by subcutaneous injection, and were symmetrically implanted on the front or back parts of the flanks of each mouse. Analyses of the results were restricted to symmetrical, that is, within pair, comparisons. The tumours were allowed to grow for 4 weeks before the mice were killed and subjected to surgical removal of the tumours. Tumours/Matrigel implants were immediately photographed and weighed. Afterwards, the tumours were divided for further analyses of tumour histology and tumour haemoglobin content.

Tumour histology
----------------

One part of each tumour was fixed with 10% neutralised formalin overnight, embedded in paraffin, and sectioned at the thickness of 4 *μ*m. For histological analysis, the sections were subjected to haematoxylin and eosin (HE) staining. The sections were observed, and the images were recorded using a Nikon Eclipse 90i microscope (Nikon Corporation, Tokyo, Japan).

Measurement of haemoglobin in tumour plugs
------------------------------------------

A portion of each tumour was rinsed with saline, placed on dry ice, and air dried for ⩾12 h in a hood. Dehydration of tumour plugs was employed as a haemoglobin concentrating procedure that enabled us to analyse the plugs with minor angiogenesis. Each dried tumour plug was weighed, and then lysed in 1 ml 0.1% Triton-100 for 2 h at room temperature. Afterwards, the lysates were thoroughly mixed by repeated pipetting, and then centrifuged at 15 000 g for 15 min. The supernatants were collected and stored at 4 °C. Upon measurements, 150 *μ*l supernatant was mixed with 2500 *μ*l colourimetric reagent of haemoglobin analysis kit A071 (Nanjing Jiancheng Bioengineering Institute, Nanjing, China) and incubated in a 37 °C water bath for 20 min. When the colourimetric reaction was completed, absorbance of the samples was measured at 510 nm using a Multiskan MK3 microplate spectrophotometer (Thermo Scientific, Waltham, MA, USA). The results are reported as angiogenesis index that is the product of tumour plug weight and haemoglobin content in mg per g of dried tumour plug. Hence, the angiogenesis index reflects both tumour size and blood content/angiogenesis in the tumour plugs.

Statistics
----------

Data are presented as means±s.e.m. Comparisons between treatments were analysed by one-way ANOVA followed by Newman--Keuls test or two-way ANOVA where appropriate using GraphPad 5 (GraphPad Software, San Diego, CA, USA). *P*\<0.05 was deemed statistically significant.

Results
=======

Platelet releasates enhanced the proliferation of breast cancer cells under a serum-free condition
--------------------------------------------------------------------------------------------------

We and others have previously demonstrated that PAR1 and PAR4 stimuli evoke distinct pro- and anti-angiogenic factor release of platelets ([@bib4]), and that PAR1-PR and PAR4-PR regulate angiogenic activities of endothelial cells with different potentials ([@bib10]). To determine whether distinct platelet release of angiogenic factors also differently regulates the behaviours of cancer cells, we first investigated the effects of PAR1-PR and PAR4-PR on breast cancer cell proliferation. The MCF-7 and MDA-MB-231 cells were incubated with supernatant from resting platelets (control), PAR1-PR, or PAR4-PR for 96 h under a serum-free condition, and cell proliferation was monitored using the colourimetric assay CCK-8. We found that supplementation of PAR1-PR and PAR4-PR, but not PAR1-AP or PAR4-AP, significantly increased the proliferation of both MCF-7 ([Figure 1A](#fig1){ref-type="fig"}, upper panel) and MDA-MB-231 cells ([Figure 1A](#fig1){ref-type="fig"}, lower panel), and that the enhancements led to faster and more intensive cell proliferation. To further characterise this effect, we examined cell division using CFSE staining. As shown in [Figure 1B](#fig1){ref-type="fig"}, CFSE fluorescence signals of both MCF-7 and MDA-MB-231 cells were dramatically reduced after 96 h of culture, indicating marked cancer cell proliferation. In the presence of PAR1-PR and PAR4-PR, the CFSE signals of both cell types were further reduced in a similar manner, and the percentages of CFSE-dim cells at 96 h were significantly higher ([Figure 1B and C](#fig1){ref-type="fig"}), suggesting that PAR1-PR and PAR4-PR accelerated cell division of MCF-7 and MDA-MB-231 cells similarly. However, supplementation of cultured MCF-7 cells with control vehicle, PAR1-PR, or PAR4-PR did not alter Annexin V^+^ cells ([Figure 1D](#fig1){ref-type="fig"}, upper panels), with the percentages of Annexin V^+^ MCF-7 at 5.1±1.6%, 5.6±1.5%, and 5.9±1.6%, respectively. The same was also true for MDA-MB-231 cells ([Figure 1D](#fig1){ref-type="fig"}, lower panels). The results suggested that either PAR1-PR or PAR4-PR had no influence on apoptosis of these breast cancer cells during 72 h of cell culture.

Platelet releasates promoted cancer cell-induced endothelial cell tube formation
--------------------------------------------------------------------------------

Angiogenesis is critical for cancer growth and metastasis. Effects of platelet releasates on breast cancer cell-regulated angiogenic activities of cultured endothelial cells were thus studied. The HUVECs incubated on Matrigel over 6 h had limited capillary-like tube formation ([Figure 2A](#fig2){ref-type="fig"}, up-left panel). Supplementation of platelet releasates enhanced endothelial tube formation, and in line with our previous studies ([@bib10]), PAR1-PR promoted capillary-like tube formation of HUVECs more potently than PAR4-PR ([Figure 2A and B](#fig2){ref-type="fig"}). Interestingly, co-incubation of HUVECs with breast cancer cells also facilitated tube formation. The enhancement was much more marked with MDA-MB-231 cells than with MCF-7 cells, probably indicating a more aggressive nature of MDA-MB-231 cells. Moreover, the combination of platelet releasate with either MDA-MB-231 or MCF-7 cells further promoted endothelial tube formation ([Figure 2A](#fig2){ref-type="fig"}). When endothelial angiogenic activities were quantified and assessed as branch points of capillary network, it was found that MDA-MB-231 cells increased the branch points of HUVEC capillary-like network from 4.8±1.3 of HUVECs alone to 66.8±20.5, and that supplementation of PAR1-PR further increased the branch points to 90.4±21.3 (*P*\<0.05, as compared with MDA-MB-231 cell co-incubation only; [Figure 2B](#fig2){ref-type="fig"}). Supplementation of PAR4-PR only showed a weak trend to enhance MDA-MB-231 cell-induced tube formation, with a slightly higher branch points at 75.0±17.7. Similar collaborative enhancements on endothelial tube formation were also seen with MCF-7 cells and platelet releasates, although the enhancements were less potent as compared with those with MDA-MB-231 cells ([Figure 2B](#fig2){ref-type="fig"}). Together, these results indicate that platelet releasates can enhance angiogenic potentials of breast cancer cells.

VEGFR-2 and integrin mediated platelet releasate-enhanced breast cancer cell proliferation
------------------------------------------------------------------------------------------

To determine the mechanism by which platelet releasates increased the proliferation of breast cancer cells, we investigated the possible roles of multiple platelet-derived angiogenic factors. In the absence of platelet releasates, the proliferation of MCF-7 ([Figure 3A](#fig3){ref-type="fig"}) or MDA-MB-231 cells ([Figure 3B](#fig3){ref-type="fig"}) was not affected by the VEGFR-2 inhibitor Ki8751, the CXCR4 inhibitor ADM3100, or the integrin blocking peptide RGDS. In the presence of either PAR1-PR or PAR4-PR, the proliferation of MCF-7 and MDA-MB-231 cells was markedly increased. The enhancements were totally inhibited by VEGFR-2 inhibition. Interestingly, integrin blockage by the pan integrin inhibitor RGDS peptide also abolished PAR1-PR- and PAR4-PR-enhanced proliferation in MCF-7 and MDA-MB-231 cells. However, CXCR4 blockade had no effects on platelet releasate-dependent breast cancer cell proliferation. Thus, these data demonstrated that the proliferation-enhancing effects of PAR1-PR and PAR4-PR on MCF-7 and MDA-MB-231 cells were mediated by VEGFR-2 and integrins.

Platelet releasates promoted breast cancer cell proliferation via PI3K/PKC pathway
----------------------------------------------------------------------------------

To clarify signalling pathways downstream of platelet releasate-enhanced proliferation of breast cancer cells, several kinase-specific small molecular inhibitors, including the PI3K inhibitor LY294002, the ERK inhibitor U0126, the p38 inhibitor SB203580, the PKC inhibitor Ro318220, and the Src kinase inhibitor PP2, were employed during 96 h cultures of breast cancer cells. As expected, supplementation of platelet releasates markedly increased breast cancer cell proliferation, and the stimulatory effects of PAR1-PR and PAR4-PR on either MCF-7 or MDA-MB-231 cells were similar. Among MCF-7 cells ([Figure 4A](#fig4){ref-type="fig"}), PI3K and PKC blockade abolished platelet releasate-dependent enhancements, and reduced cell proliferation to the same levels of MCF-7 cells cultured without platelet releasates, indicating a critical role of PI3K and PKC signalling in cell proliferation. The Src and ERK inhibition also diminished PAR1-PR- and PAR4-PR-enhanced breast cancer proliferation, whereas MAPK p38 intervention had little impact. Among MDA-MB-231 cells ([Figure 4B](#fig4){ref-type="fig"}), more clearcut inhibitions were seen, and all the inhibitors diminished PAR1-PR- and PAR4-PR-dependent enhancements of MDA-MB-231 cell proliferation.

Impact of platelet releasates on MDA-MB-231 tumour growth *in vivo*
-------------------------------------------------------------------

The presence of PAR1-PR or PAR4-PR significantly enhanced tumour growth of subcutaneously implanted MDA-MB-231 cells in nude mice. This was evidenced by our observation showing that supplementation of either PAR1-PR or PAR4-PR markedly increased MDA-MB-231 tumour growth ratios as compared with MDA-MB-231 cancer cell implants with vehicle ([Figure 5A](#fig5){ref-type="fig"}). Moreover, the tumour growth ratio of MDA-MB-231 tumour with PAR1-PR was higher than that with PAR4-PR. Light microscopic observation of histological sections ([Figure 5B--D](#fig5){ref-type="fig"}) showed that there was significant breast cancer cell proliferation in the tumour plugs, and that cancer cells grew into lobular cell masses. In the tumour implanted with vehicle ([Figure 5B](#fig5){ref-type="fig"}), there were considerable amounts of noncancer cell tissues between lobular cancer cell mass, and the blood vessels were sparse. In contrast, higher densities of breast cancer cells and blood vessels were observed in the tumours that were implanted with PAR1-PR ([Figure 5C](#fig5){ref-type="fig"}) and PAR4-PR ([Figure 5D](#fig5){ref-type="fig"}).

Five pairs of contralateral implanted MDA-MB-231 tumour with PAR1-PR or PAR4-PR are shown in [Figure 6A](#fig6){ref-type="fig"}. It can be clearly seen that most of the tumours implanted with PAR1-PR were larger (mean tumour weight 0.44±0.07 g) than the ones with PAR4-PR (0.31±0.06 g; *P*\<0.05). The only exception, the upper PAR4-PR plug, appeared to be larger, but was actually elongated/thin and not heavier than the countering PAR1-PR plug. Using tumour weight of PAR1-PR-containing tumour as the standard, the tumour growth ratio of PAR1-PR-containing tumour was significantly higher than that of PAR4-PR-containing tumour ([Figure 6B](#fig6){ref-type="fig"}). Furthermore, when haemoglobin contents in the tumours were measured and the angiogenesis indexes were calculated, the index of PAR1-PR-containing tumours was significantly higher than that of PAR4-PR-containing tumours ([Figure 6C](#fig6){ref-type="fig"}), indicating more profound angiogenesis in the presence of PAR1-PR.

Discussion
==========

The present work demonstrated that platelet releasates promoted the proliferation of the breast cancer cell lines MCF-7 and MDA-MB-231 through VEGF--integrin cooperative signalling. Platelet releasates and breast cancer cells each enhanced capillary-like tube formation of HUVECs, and the combination of platelet releasates and breast cancer cells further enhanced the tube formation. Moreover, selective release of platelet pro-angiogenic regulators exaggerated breast cancer growth *in vivo*, and the distinct effect was associated with intensified angiogenesis in the tumours.

A series of recent reports from several laboratories indicate that platelets store pro-angiogenic and anti-angiogenic regulators in separate *α*-granules, and that platelets selectively release pro- or anti-angiogenic regulators upon different stimuli ([@bib19]; [@bib11]; [@bib4]). Although some concerns have also been raised that selective release of platelet angiogenic regulators may be activation intensity and/or secretion kinetics dependent ([@bib12]; [@bib28]), selective release of counteracting angiogenic regulators remains a tempting intervention target for the development of a platelet-targeted cancer intervening approach. It has been reported that selective platelet release of pro-angiogenic regulators by ADP stimulation promoted whereas selective platelet release of anti-angiogenic regulators by TXA~2~ stimulation inhibited angiogenic responses of endothelial cells ([@bib1]). We have, however, shown that both PAR1-PR and PAR4-PR enhanced angiogenic activities of endothelial progenitor cells, and that the enhancement by pro-angiogenic regulator-rich PAR1-PR was more potent ([@bib10]). Supporting and expanding our earlier findings, the present work demonstrated that both PAR1-PR and PAR4-PR enhanced the proliferation of breast cancer cells *in vitro*, and that both of them promoted tumour growth *in vivo* of implanted MDA-MB-231 cells. Although there was no major difference between PAR1-PR- and PAR4-PR-enhanced breast cancer cell proliferation *in vitro*, PAR1-PR enhanced tumour growth *in vivo* more profoundly. The favourable enhancement of tumour growth by PAR1-PR was likely caused by increased angiogenesis. The latter was supported by the evidence showing that PAR1-PR, alone or in combination with cancer cells, promoted more profound endothelial cell tube formation *in vitro*, and that angiogenesis index of tumours implanted with PAR1-PR was higher than that with PAR4-PR. Hence, our data suggest that selective release of platelet anti-angiogenic regulators upon certain stimuli (e.g., by PAR4 stimulation) may not be used as a simple platelet-targeted approach for the intervention of tumour growth.

The VEGF is a potent inducer of angiogenesis that is required for a wide variety of physiological and pathological processes, including tumour progression. The present study showed that VEGFR-2 blockade abolished platelet releasate-enhanced breast cancer cell proliferation, implying that VEGF is the prominent mediator of the platelet releasates promoting MCF-7 and MDA-MB-231 cell proliferation. Our findings also support the notion that VEGF is not only a potent angiogenic regulator but also a versatile actor in cancer cell biology, for example, cancer cell survival and proliferation, as well as resistance to chemotherapy ([@bib5]). Interestingly, our data showed that integrin inhibition by RGDS strongly diminished platelet releasate-promoted proliferation of breast cancer cells, and to the same inhibitory extent as by VEGFR-2 blockade. The observation highlighted the close and important collaboration between integrin and growth factor receptors ([@bib20]). It has previously been shown that VEGF directly bound to *α*9*β*1 integrin, and that VEGF-induced adhesion, migration, and angiogenesis of endothelial cells depended on cooperative signal inputs of *α*9*β*1 integrin and VEGFR-2 ([@bib29]). Of note, both VEGFR-2 signalling and *α*9*β*1 outside-in signalling operated through PI3K--PKC--MAPK pathway ([@bib20]; [@bib22]). Indeed, the present study showed that either PI3K or PKC inhibition completely blocked PAR1-PR- and PAR4-PR-enhanced cancer cell proliferation. Hence, our findings suggest that VEGF from the platelet releasates is the key growth factor stimulating breast cancer cell proliferation via VEGFR2--integrin cooperative signalling through PI3K/PKC signalling axis.

In conclusion, platelet releasates promote cancer cell proliferation mainly through VEGF triggered VEGFR2--integrin cooperative signalling via PI3K/PKC signalling pathway. Platelet releasates and cancer cells also cooperate to promote angiogenic activities of endothelial cells. Pro-angiogenic factor-rich PAR1-PR promotes breast cancer growth more markedly than anti-angiogenic factor-rich PAR4-PR by promoting more intense angiogenesis in the tumour.
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![**Platelet releasates enhance cell proliferation without affecting apoptosis of breast cancer cells.** Breast cancer cell lines MCF-7 and MDA-MB-231 were treated with or without 10% (final concentration) of PAR1-PR or PAR4-PR under a serum-free culture condition. (**A**) Cell proliferation rate was detected at indicated time points using a CCK assay. The fold increases of OD values, proportional to the increase of cell numbers, were referred to those at time 0. Data are presented as mean±s.e.m. from at least five independent experiments. ^\#^*P*\<0.05, ^†^*P*\<0.001 *vs* control at corresponding time points. (**B**) CFSE fluorescence intensities of breast cancer cells were determined by flow cytometry after MCF-7 and MDA-MB-231 cells were cultured without (control; black solid lines) or with PAR1-PR (blue dash lines) or PAR4-PR (red dot lines) for 96 h. (**C**) Quantification of CFSE dilution. ^\#^*P*\<0.05 *vs* control. (**D**) The MCF-7 and MDA-MB-231 cells were stained with FITC-conjugated Annexin V and PE-conjugated PI after 72 h of culture, and were examined using the Beckman Coulter F500 flow cytometer. Percentages of total apoptotic cells, that is, all Annexin-V-positive cells, were plotted. Images in (**B** and **D**) are the representatives from three independent experiments. A full colour version of this figure is available at the *British Journal of Cancer* journal online.](bjc2017214f1){#fig1}

![**Platelet releasates and cancer cells collaborate to potentiate the tube formation of endothelial cells.** Endothelial cells (ECs) were supplemented with vehicle (EC only), PAR1-PR (10%), PAR4-PR (10%), MCF-7 cells, or/and MDA-MB-231 cells at the EC/cancer cell ratio of 1 : 1. The mixtures (100 *μ*l) were added into Matrigel-coated wells and incubated at 37 °C for 6 h. (**A**) The EC tube formation was photographed using an inverted light microscope. (**B**) The branch point numbers of capillary-like structures were assessed using the Wimasis software. Data are presented as mean±s.e.m. from five independent experiments. \**P*\<0.001, ^\#^*P*\<0.05 *vs* EC only; ^ϕ^*P*\<0.05 *vs* EC+PAR4-PR; ^†^*P*\<0.05 *vs* EC+MCF-7; ^‡^*P*\<0.05 *vs* EC+MDA-MB-231. A full colour version of this figure is available at the *British Journal of Cancer* journal online.](bjc2017214f2){#fig2}

![**Blockade of vascular endothelial growth factor receptor (VEGFR) and integrin inhibits platelet releasate-enhanced breast cancer cell proliferation.** The breast cancer cell line MCF-7 (**A**) and MDA-MB-231 cells (**B**) were treated without (control) or with 10% (final concentration) PAR1-PR or PAR4-PR in the absence or presence of the VEGFR-2 inhibitor Ki8751 (0.5 *μ*[M]{.smallcaps}), the CXCR4 inhibitor AMD3100 (10 *μ*[M]{.smallcaps}), or the integrin blocking peptide RGDS (10 *μ*g ml^−1^). After 96 h of incubation, cell proliferation was assessed using a CCK assay. The percentage changes of cell proliferation were referred to the cells cultured with vehicle and without platelet releasate. Data are presented as mean±s.e.m. from four independent experiments. ^\#^*P*\<0.05, \**P*\<0.01, and ^†^*P*\<0.001 compared with corresponding treatments without inhibitors.](bjc2017214f3){#fig3}

![**Platelet releasates promote breast cancer cell proliferation through PI3K/PKC signalling.** Breast cancer cell lines MCF-7 (**A**) and MDA-MB-231 (**B**) were treated with or without 10% (final concentration) of PAR1-PR or PAR4-PR in the absence or presence of the Src kinase inhibitor PP2 (10 *μ*[M]{.smallcaps}), the PI3K inhibitor LY294002 (25 *μ*[M]{.smallcaps}), the PKC inhibitor Ro318220 (10 *μ*[M]{.smallcaps}), the ERK inhibitor U0126 (10 *μ*[M]{.smallcaps}), or the p38 inhibitor SB203580 (10 *μ*[M]{.smallcaps}). After 96 h of incubation, cell proliferation was detected using a CCK assay. Impacts of platelet releasates and signalling interventions on breast cancer cell proliferation were assessed as the percentage changes compared with the cells cultured without platelet releasate and treated with vehicle. Data are presented as mean±s.e.m. from four independent experiments. ^\#^*P*\<0.05, \**P*\<0.01, and ^†^*P*\<0.001 compared with corresponding treatments without inhibitors.](bjc2017214f4){#fig4}

![**Platelet releasates enhance tumour growth *in vivo*.** MDA-MB-231 breast cancer cells in Matrigel (10^6^ cells in 250 *μ*l) were subcutaneously implanted without or with 10% (final concentration) PAR1-PR or PAR4-PR in female nude mice. After 4 weeks, tumours were surgically removed, weighted, and sectioned for HE staining. (**A**) Tumour growth ratios were calculated using the following formula: tumour growth ratio=(tumour weight with vehicle (or PAR1-PR or PAR4-PR))/tumour weight with vehicle. Mean±s.e.m. from eight tumour pairs are plotted. \**P*\<0.05 *vs* vehicle, ^†^*P*\<0.05 *vs* PAR1-PR. Representative images of MDA-MB-231 cell tumour sections with vehicle (**B**), PAR1-PR (**C**), and PAR4-PR (**D**) are shown. Black asterisks indicate cancer tissues, and white arrows indicate vessels in the tumour plugs. A full colour version of this figure is available at the *British Journal of Cancer* journal online.](bjc2017214f5){#fig5}

![**The PAR1-PR enhances tumour growth more potently than PAR4-PR.** The MDA-MB-231 breast cancer cells in Matrigel (10^6^ cells in 250 *μ*l, containing 10% PAR1-PR or PAR4-PR) were subcutaneously implanted in female nude mice. After 4 weeks, tumours were removed, weighted, and photographed. A portion of each tumour plug was used for measurement of haemoglobin content. (**A**) Five pairs of symmetrically implanted tumour plugs with PAR1-PR or PAR4-PR are shown. (**B**) Tumour growth ratios were calculated using the following formula: tumour growth ratio=(tumour weight with PAR1-PR (or PAR4-PR))/tumour weight with PAR1-PR. Mean±s.e.m. from five tumour pairs are plotted. \**P*\<0.05 *vs* PAR1-PR. (**C**) Mean±s.e.m. of angiogenesis index of five tumour pairs are plotted. \**P*\<0.05 *vs* PAR1-PR. A full colour version of this figure is available at the *British Journal of Cancer* journal online.](bjc2017214f6){#fig6}
